Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy.

Journal: Expert opinion on drug discovery
Published Date:

Abstract

BACKGROUND: Cathepsin K (CTSK), a cysteine protease of the papain family, exhibits high expression in activated osteoclasts, making it a key therapeutic target for osteoporosis. However, there are currently no CTSK inhibitors available for clinical use.

Authors

  • Qi Li
    The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
  • Xue-Chun Han
    Beijing Key Laboratory of Diabetes Research and Care, Beijing Diabetes Institute, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Si-Rui Zhou
    Beijing Key Laboratory of Diabetes Research and Care, Beijing Diabetes Institute, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Yu Lu
    Faw-volkswagen Automative Co., Changchun, China.
  • Yu-Ji Wang
    Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
  • Jin-Kui Yang
    Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Keywords

No keywords available for this article.